Oramed Pharmaceuticals Stock (NASDAQ:ORMP)


OwnershipChart

Previous Close

$2.38

52W Range

$2.00 - $3.67

50D Avg

$2.38

200D Avg

$2.43

Market Cap

$96.14M

Avg Vol (3M)

$136.66K

Beta

1.77

Div Yield

-

ORMP Company Profile


Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

May 01, 2007

Website

ORMP Performance


Peer Comparison


TickerCompany
LXRXLexicon Pharmaceuticals, Inc.
ALDXAldeyra Therapeutics, Inc.
CKPTCheckpoint Therapeutics, Inc.
CRVSCorvus Pharmaceuticals, Inc.
MCRBSeres Therapeutics, Inc.
INZYInozyme Pharma, Inc.
XFORX4 Pharmaceuticals, Inc.
IBRXImmunityBio, Inc.
MREOMereo BioPharma Group plc
BLRXBioLineRx Ltd.
ARDXArdelyx, Inc.
IMMXImmix Biopharma, Inc.
CYTOAltamira Therapeutics Ltd.
LPTXLeap Therapeutics, Inc.
ZURAZura Bio Limited
ELEVElevation Oncology, Inc.
TERNTerns Pharmaceuticals, Inc.
OCEAOcean Biomedical, Inc.
HEPAHepion Pharmaceuticals, Inc.
ENVBEnveric Biosciences, Inc.
PALIPalisade Bio, Inc.